Evidence map›Paper›PMID 33741729›Full record

ArticleJournal for immunotherapy of cancer2021

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.

Louise M E Müller, Gemma Migneco, Gina B Scott, Jenny Down, Sancha King, Basem Askar, Victoria Jennings, Babatunde Oyajobi, Karen Scott, Emma West and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 3 countries.

Louise M E MüllerDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Gemma MignecoDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Gina B ScottDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Jenny DownSheffield Myeloma Research Team, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Sancha KingSheffield Myeloma Research Team, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Basem AskarDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Victoria JenningsDivision of Radiotherapy and Imaging, Institute of Cancer Research, London, UK.
Babatunde OyajobiCancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Karen ScottDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.ORCID 0000-0002-5790-9579
Emma WestDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Christy RalphDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Adel SamsonDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Elizabeth J IlettDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Munitta MuthanaSheffield Myeloma Research Team, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Matt CoffeyOncolytics Biotech Inc, Calgary, Alberta, Canada.
Alan MelcherDivision of Radiotherapy and Imaging, Institute of Cancer Research, London, UK.
Christopher ParrishDepartment of Haematology, St James's University Hospital, Leeds, UK.
Gordon CookLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Michelle LawsonSheffield Myeloma Research Team, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Fiona Errington-MaisDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK F.Errington@leeds.ac.uk.ORCID 0000-0003-2155-534X
University of Leeds · GBUniversity of Sheffield · GBInstitute of Cancer Research · GBOncolytics Biotech (Canada) · CASt James's University Hospital · GBThe University of Texas Health Science Center at San Antonio · US

Funding

Cancer Research UK 21855Cancer Research UK 29039Cancer Research UK C16708/A21855Yorkshire Cancer Research L374RA
6 · The paper itself

Abstract

backgroundMultiple myeloma (MM) remains an incurable disease and oncolytic viruses offer a well-tolerated addition to the therapeutic arsenal. Oncolytic reovirus has progressed to phase I clinical trials and its direct lytic potential has been extensively studied. However, to date, the role for reovirus-induced immunotherapy against MM, and the impact of the bone marrow (BM) niche, have not been reported.

methodsThis study used human peripheral blood mononuclear cells from healthy donors and in vitro co-culture of MM cells and BM stromal cells to recapitulate the resistant BM niche. Additionally, the 5TGM1-Kalw/RijHSD immunocompetent in vivo model was used to examine reovirus efficacy and characterize reovirus-induced immune responses in the BM and spleen following intravenous administration. Collectively, these in vitro and in vivo models were used to characterize the development of innate and adaptive antimyeloma immunity following reovirus treatment.

resultsUsing the 5TGM1-Kalw/RijHSD immunocompetent in vivo model we have demonstrated that reovirus reduces both MM tumor burden and myeloma-induced bone disease. Furthermore, detailed immune characterization revealed that reovirus: (i) increased natural killer (NK) cell and CD8

conclusionThese data highlight the importance of reovirus-induced immunotherapy for targeting MM cells within the BM niche and suggest that combination with agents which boost antitumor immune responses should be a priority.

Indexed as

Oncolytic VirotherapyAnimalsBone MarrowCD8-Positive T-LymphocytesCell Line, TumorCoculture TechniquesCytokinesCytotoxicity, ImmunologicFemaleHumansKiller Cells, NaturalMaleMiceMice, Inbred C57BLMultiple MyelomaOncolytic VirusesCytokinesadaptive immunityimmunityimmunotherapyinnate immunityoncolytic viruses

Identifiers

PMID33741729
PMCPMC7986878
OpenAlexW3137265803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.